Qualigen Therapeutics Inc (QLGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qualigen Therapeutics Inc (QLGN) has a cash flow conversion efficiency ratio of -0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.14 Million) by net assets ($38.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Qualigen Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Qualigen Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Qualigen Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check QLGN cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Qualigen Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qualigen Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Helios Energy Ltd
AU:HE8
|
-0.020x |
|
RenX Enterprises Corp.
NASDAQ:RENX
|
-1.557x |
|
WORK Medical Technology Group LTD Ordinary Shares
NASDAQ:WOK
|
0.427x |
|
Masivo Silver Corp
V:MASS
|
-10.665x |
|
Mha Ltd
LSE:MHA
|
N/A |
|
Novakand Pharma AB (publ)
ST:LARK
|
-0.029x |
|
Silo Pharma Inc
NASDAQ:SILO
|
-0.145x |
|
XTL Biopharmaceuticals Ltd
TA:XTLB
|
-0.055x |
Annual Cash Flow Conversion Efficiency for Qualigen Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Qualigen Therapeutics Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see QLGN stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.68 Million | $-6.33 Million | -2.362x | -148.22% |
| 2023-12-31 | $-2.10 Million | $-10.30 Million | 4.898x | +424.16% |
| 2022-12-31 | $8.77 Million | $-13.25 Million | -1.511x | -69.93% |
| 2021-12-31 | $16.56 Million | $-14.73 Million | -0.889x | -66.77% |
| 2020-12-31 | $18.29 Million | $-9.76 Million | -0.533x | -1123.08% |
| 2019-12-31 | $1.10 Million | $57.33K | 0.052x | +103.67% |
| 2018-12-31 | $9.39 Million | $-13.33 Million | -1.420x | -286.43% |
| 2017-12-31 | $20.13 Million | $-7.40 Million | -0.368x | +90.08% |
| 2016-12-31 | $4.10 Million | $-15.21 Million | -3.707x | -851.36% |
| 2015-12-31 | $14.68 Million | $-5.72 Million | -0.390x | +42.48% |
| 2014-12-31 | $1.71 Million | $-1.16 Million | -0.677x | -112.12% |
| 2013-12-31 | $-350.25K | $-1.96 Million | 5.587x | +271.69% |
| 2012-12-31 | $946.03K | $-3.08 Million | -3.254x | -- |
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS tha… Read more